About
Arie Belldegrun is an Israeli-American urologic oncologist, billionaire businessman, and investor. Born in Tel Aviv, Israel, he pursued a distinguished career in medicine and biotechnology. He is known for founding and co-founding several prominent biotech companies, including Agensys, Cougar Biotechnology, Kite Pharma, and Allogene Therapeutics. Following the acquisition of Kite Pharma by Gilead Sciences for $11.9 billion, he established Bellco Capital, his family office, and co-founded Vida Ventures, a life sciences investment firm. He is also involved with Two River Group, Breakthrough Properties, and Symbiotic Capital, focusing on various aspects of the life sciences industry, from venture capital to real estate.
Portfolio
Investment activity
1 portfolio exit on record.
Portfolio by sector
Q&A
- What is Arie Belldegrun's primary investment focus?
- Arie Belldegrun primarily focuses on the Health Tech & Life Sciences sector, with all recorded portfolio companies and exits falling within this area.
- Can you name a notable portfolio company for Arie Belldegrun?
- Arie Belldegrun's notable portfolio company is Entera Bio, which specializes in the oral delivery of therapeutic proteins.
- Has Arie Belldegrun had any exits from their portfolio?
- Yes, Arie Belldegrun had an exit in July 2018 with Entera Bio, which went public on NASDAQ with a valuation of $91M.
- What type of funding stage has Arie Belldegrun participated in?
- Arie Belldegrun has participated in the Convertible Debt funding stage, with one recorded instance.
- When was Arie Belldegrun's most recent investment activity?
- Arie Belldegrun's most recent recorded investment activity was in July 2016.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Radar intelligence
Patents
| EPO | 10 |
|---|